380 results on '"Oesterreich S"'
Search Results
2. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
3. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine
4. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study
5. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression
6. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2
7. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
8. O43: CLINICAL IMPACT OF GENE FUSIONS IN BREAST CANCER BRAIN METASTASES
9. A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone
10. Developmental and Hormonal Signals Dramatically Alter the Localization and Abundance of Insulin Receptor Substrate Proteins in the Mammary Gland
11. Abstract P5-04-21: FGFR4 is a novel druggable target for recurrent ER-positive breast cancers
12. Abstract P2-01-09: ESR1 mutations drive breast cancer metastasis by context-dependent alterations in adhesive and migratory properties
13. Abstract P3-06-03: Copy number analysis identifies ESR1 and MDM4 as drivers of progression in invasive lobular breast carcinoma
14. Abstract PD7-02: Novel human cell line xenograft models of ERα-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers
15. Abstract P6-12-01: Withdrawn
16. Abstract P6-04-01: Identification and targeting of clinically actionable genes in bone metastases
17. Abstract P3-10-05: BRCA1/2 alterations are present at significant rates across breast cancer subtypes and are associated with a high genome-wide loss of heterozygosity signature
18. Abstract PD7-03: Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma
19. Estrogen Receptor Corepressors –Mechanism of Action and Role in Breast Tumorigenesis
20. Clinical and histological characteristics of peritoneal metastases of ILC
21. PO-143 Recurrent transcriptional remodelling events represent clinically actionable targets in breast cancers brain metastasis
22. Abstract P5-17-01: Lobular breast cancer alliance - Advocates advancing research, screening, treatment and follow-up care for lobular breast disease
23. Abstract MS2-2: Understanding the unique biology of ILC
24. Abstract P4-05-02: Differential regulation of ER protein-turnover in invasive lobular carcinoma cells
25. Abstract PD8-05: Genomic profiling of metastatic invasive lobular carcinoma reveals unique genomics and therapeutic opportunities
26. Abstract P1-03-03: Invasive lobular carcinoma and invasive ductal carcinoma differ in immune response, translation efficiency and metabolic rate
27. Abstract PD4-09: Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma
28. Abstract P1-01-07: Clinical and histological characteristics of peritoneal metastases of invasive lobular breast cancer
29. Abstract P5-06-03: Generation and characterization of a novel invasive lobular breast carcinoma cell line WCRC-25
30. Abstract PD8-08: ESR1 mutations confer novel metastatic functions in genome-edited breast cancer cell models
31. Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers
32. Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen
33. Abstract P3-04-02: Differential turnover of estrogen receptor alpha in invasive lobular carcinoma
34. Abstract P3-07-04: WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cells
35. Abstract P6-07-07: ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer
36. Abstract PD1-05: Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations
37. Abstract P6-11-07: Methylation of BRCA1 and response to the PARP inhibitor veliparib
38. The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer
39. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression
40. Abstract PD2-08: Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer
41. Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma
42. Abstract P6-08-02: Developing in vitro models of ductal carcinoma in situ from primary tissue
43. Abstract P3-04-02: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
44. A novel orthotopic mouse model of epithelial ovarian carcinoma demonstrating progression from early stage disease to carcinomatosis in both immune-competent and immune-deficient models
45. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
46. MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years
47. Abstract P5-09-03: Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance
48. Abstract P4-05-03: Unique genetic, epigenetic, and transcriptomic changes in premenopausal breast cancer suggest novel strategies for therapy
49. Abstract P6-06-46: Treatment decisions and five year outcomes of the oncotype Dx test: An independent assessment
50. Abstract P2-11-10: Intra-tumor heterogeneity affects multi-gene test prognostic risk stratification
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.